I first became concerned about unaffordable drug prices when I did one of my first-year research rotations in a lab that studied the hepatitis C virus. The timing of my rotation was in the midst of the (continuing) hepatitis C epidemic and just after the development of Harvoni, an exorbitantly expensive cure ($50,000–$100,000). I learned(...)